JPRN-jRCT2080221718未知2 期
ONO-8025 Phase II Study -A Multicenter Randomized Double-blind Study in Chronic Obstructive Pulmonary Disease (COPD) Patients
ONO PHARMACEUTICAL CO.,LTD.0 个研究点目标入组 26 人开始时间: 2012年2月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 40age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Patients with GOLD stage II or III COPD
排除标准
- •1.Presence or history of bronchial asthma, or presence of lung cancer, bronchiectasis, diffuse panbronchiolitis, sinoatrial syndrome, interstitial pneumonia, tuberculosis, or sequelae of tuberculosis
研究者
相似试验
未知
2 期
ONO-2745 IIb/III StudyPatients undergoing surgery requiring general anesthesiaJPRN-jRCT2080221928ONO PHARMACEUTICAL CO.,LTD.325
未知
2 期
ONO-2745 Phase II StudyPostoperative patients requiring sedation during artificial ventilation in intensive care unit.JPRN-jRCT2080221927ONO PHARMACEUTICAL CO.,LTD.90
未知
3 期
ONO-7847 Phase 3 StudyJPRN-jRCT2080220800ONO PHARMACEUTICAL CO.,LTD.344
已完成
2 期
ONO-4538 Phase 2 study (ONO-4538-88/TASUKI-88)Malignancies (Gastric Cancer/Non-Small Cell Lung Cancer)JPRN-jRCT2080225262ONO PHARMACEUTICAL CO., LTD.60
已完成
2 期
ONO-4538 Phase II Study (ONO-4538-91/TASUKI-91)Patients with unresectable or recurrent biliary tract cancer (including intrahepatic bile duct cancer, extrahepatic bile duct cancer, gallbladder cancer, and duodenal papilla cancer) that is refractory or intolerant to gemcitabine-based and S-1-based regimens with CPS >=1.JPRN-jRCT2080225006ONO PHARMACEUTICAL CO., LTD.80